Skip Navigation

British Medical Bulletin 2004 70(1):1-14; doi:10.1093/bmb/ldh021
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Finn, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Finn, A.
Related Collections
Right arrow Infectious Diseases
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published online 31 August 2004

British Medical Bulletin, Vol. 70 © The British Council 2004; all rights reserved

Bacterial polysaccharide–protein conjugate vaccines

Adam Finn

Institute of Child Health, Department of Clinical Sciences South Bristol, University of Bristol, Bristol, UK

Correspondence to: Adam Finn, Professor of Paediatrics, Institute of Child Health, Level 6, UBHT Education Centre, Upper Maudlin Street, Bristol BS2 8AE, UK. E-mail: adam.finn{at}bristol.ac.uk

Following demonstration that chemical conjugation of polysaccharide antigens to proteins could enhance their immunogenicity in the 1920s, interest in this approach to primary prevention of bacterial infections waned with the development and widespread use of antibiotics. Emergence of resistant bacteria rekindled interest in the late 20th century, which saw extremely rapid development and implementation of several vaccines which are already rapidly changing the epidemiology of childhood infections with Haemophilus influenzae type b, Streptococcus pneumoniae and Neisseria meningitidis. Others such as Group B streptococcus and Salmonella typhi infections may soon follow. However, several important questions about the immunology of these antigens remain unanswered and the long-term implications of reducing or eliminating the circulation of organisms which are more commonly nasopharyngeal commensals than pathogenic invaders are uncertain.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CVIHome page
D. Chiavolini, S. Weir, J. R. Murphy, and L. M. Wetzler
Neisseria meningitidis PorB, a Toll-Like Receptor 2 Ligand, Improves the Capacity of Francisella tularensis Lipopolysaccharide To Protect Mice against Experimental Tularemia
Clin. Vaccine Immunol., September 1, 2008; 15(9): 1322 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
H.-H. Yang, S. J. Mascuch, L. C. Madoff, and L. C. Paoletti
Recombinant Group B Streptococcus Alpha-Like Protein 3 Is an Effective Immunogen and Carrier Protein
Clin. Vaccine Immunol., July 1, 2008; 15(7): 1035 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. S. Kirimanjeswara, P. B. Mann, M. Pilione, M. J. Kennett, and E. T. Harvill
The Complex Mechanism of Antibody-Mediated Clearance of Bordetella from the Lungs Requires TLR4
J. Immunol., December 1, 2005; 175(11): 7504 - 7511.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.